BioMarin Pharmaceutical Inc. (FRA:BM8)

Market Cap	10.45B -11.0%
Revenue (ttm)	2.64B +12.4%
Net Income	443.55M +61.5%
EPS	2.28 +59.5%
Shares Out	n/a
PE Ratio	23.56
Forward PE	14.36
Dividend	n/a
Ex-Dividend Date	n/a

Volume	65
Average Volume	48
Open	53.70
Previous Close	52.56
Day's Range	53.70 - 53.70
52-Week Range	43.86 - 68.96
Beta	n/a
RSI	66.18
Earnings Date	Feb 23, 2026

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 3,040
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BM8

Financial Performance

In 2024, BioMarin Pharmaceutical's revenue was $2.85 billion, an increase of 17.97% compared to the previous year's $2.42 billion. Earnings were $426.86 million, an increase of 154.62%.

Financial numbers in USD